Kindred Biosciences Inc (NASDAQ:KIN) has received a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.88.

KIN has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. HC Wainwright initiated coverage on shares of Kindred Biosciences in a research note on Friday, November 17th. They issued a “buy” rating and a $9.50 price objective on the stock. B. Riley reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Kindred Biosciences in a research note on Monday, November 20th. Finally, ValuEngine raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, December 1st.

Kindred Biosciences (NASDAQ:KIN) remained flat at $$8.15 on Monday. 218,307 shares of the company traded hands, compared to its average volume of 69,170. Kindred Biosciences has a 12 month low of $4.15 and a 12 month high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. equities analysts anticipate that Kindred Biosciences will post -1.19 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in KIN. Dimensional Fund Advisors LP boosted its stake in Kindred Biosciences by 2.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,369,688 shares of the biopharmaceutical company’s stock valued at $9,656,000 after acquiring an additional 34,735 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Kindred Biosciences by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 4,954 shares during the last quarter. Trexquant Investment LP acquired a new stake in Kindred Biosciences in the second quarter worth $120,000. Schwab Charles Investment Management Inc. acquired a new stake in Kindred Biosciences in the second quarter worth $306,000. Finally, Rhumbline Advisers acquired a new stake in Kindred Biosciences in the second quarter worth $197,000. 66.85% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Kindred Biosciences Inc (KIN) Receives Consensus Recommendation of “Buy” from Brokerages” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/kindred-biosciences-inc-kin-receives-consensus-recommendation-of-buy-from-brokerages/1768533.html.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.